Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103362546> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2103362546 endingPage "128" @default.
- W2103362546 startingPage "121" @default.
- W2103362546 abstract "Breakthrough pain is common among patients with cancer and presents challenges to effective pain management. Breakthrough pain is characterized by rapid onset, severe intensity, and duration typically lasting <1 h. Thus, optimal relief from breakthrough pain is best attained by administering analgesics with dissolution times and bioavailabilities that closely match the onset and duration of breakthrough pain. The objective of this study was to assess complete disintegration time of three different doses of sublingual fentanyl tablets in opioid-tolerant patients.This was a single-center, non-randomized, open-label study. Opioid-tolerant adult patients (N = 30) with chronic pain were assigned to one of three dose groups and self-administered a single 100, 200, or 300 μg sublingual fentanyl tablet (Abstral(®), Galena Biopharma, Portland, OR, USA). Time to complete disintegration was measured by each patient with a stopwatch and independently verified by study personnel.Disintegration time (mean ± SD) for sublingual fentanyl tablets (all doses) was 88.2 ± 55.1 s. Mean disintegration times tended to be slightly longer for the 200 μg (96.7 ± 57.9 s) and 300 μg doses (98.6 ± 64.8 s) compared to the 100 μg dose (69.5 ± 40.5 s). Differences were not statistically significant. Disintegration time was not significantly different between men and women and was not affected by age.Sublingual fentanyl tablets dissolved rapidly (average time <2 min) in all patients, with the higher doses taking slightly more time to dissolve." @default.
- W2103362546 created "2016-06-24" @default.
- W2103362546 creator A5065281272 @default.
- W2103362546 date "2013-11-19" @default.
- W2103362546 modified "2023-09-27" @default.
- W2103362546 title "An Evaluation of Total Disintegration Time for Three Different Doses of Sublingual Fentanyl Tablets in Patients with Breakthrough Pain" @default.
- W2103362546 cites W1965442837 @default.
- W2103362546 cites W2011873005 @default.
- W2103362546 cites W2051575873 @default.
- W2103362546 cites W2053986063 @default.
- W2103362546 cites W2077139817 @default.
- W2103362546 cites W2090900919 @default.
- W2103362546 cites W2101328937 @default.
- W2103362546 cites W2110075393 @default.
- W2103362546 cites W2115330889 @default.
- W2103362546 cites W2117952151 @default.
- W2103362546 cites W2120849181 @default.
- W2103362546 cites W2123593017 @default.
- W2103362546 cites W2162296777 @default.
- W2103362546 doi "https://doi.org/10.1007/s40122-013-0019-6" @default.
- W2103362546 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4107913" @default.
- W2103362546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25135150" @default.
- W2103362546 hasPublicationYear "2013" @default.
- W2103362546 type Work @default.
- W2103362546 sameAs 2103362546 @default.
- W2103362546 citedByCount "4" @default.
- W2103362546 countsByYear W21033625462015 @default.
- W2103362546 countsByYear W21033625462016 @default.
- W2103362546 countsByYear W21033625462017 @default.
- W2103362546 crossrefType "journal-article" @default.
- W2103362546 hasAuthorship W2103362546A5065281272 @default.
- W2103362546 hasBestOaLocation W21033625461 @default.
- W2103362546 hasConcept C121608353 @default.
- W2103362546 hasConcept C126322002 @default.
- W2103362546 hasConcept C170493617 @default.
- W2103362546 hasConcept C2778904085 @default.
- W2103362546 hasConcept C2779350572 @default.
- W2103362546 hasConcept C2781063702 @default.
- W2103362546 hasConcept C2781072394 @default.
- W2103362546 hasConcept C2909746581 @default.
- W2103362546 hasConcept C42219234 @default.
- W2103362546 hasConcept C71924100 @default.
- W2103362546 hasConceptScore W2103362546C121608353 @default.
- W2103362546 hasConceptScore W2103362546C126322002 @default.
- W2103362546 hasConceptScore W2103362546C170493617 @default.
- W2103362546 hasConceptScore W2103362546C2778904085 @default.
- W2103362546 hasConceptScore W2103362546C2779350572 @default.
- W2103362546 hasConceptScore W2103362546C2781063702 @default.
- W2103362546 hasConceptScore W2103362546C2781072394 @default.
- W2103362546 hasConceptScore W2103362546C2909746581 @default.
- W2103362546 hasConceptScore W2103362546C42219234 @default.
- W2103362546 hasConceptScore W2103362546C71924100 @default.
- W2103362546 hasIssue "2" @default.
- W2103362546 hasLocation W21033625461 @default.
- W2103362546 hasLocation W21033625462 @default.
- W2103362546 hasLocation W21033625463 @default.
- W2103362546 hasLocation W21033625464 @default.
- W2103362546 hasOpenAccess W2103362546 @default.
- W2103362546 hasPrimaryLocation W21033625461 @default.
- W2103362546 hasRelatedWork W1426424911 @default.
- W2103362546 hasRelatedWork W1965640570 @default.
- W2103362546 hasRelatedWork W1976091872 @default.
- W2103362546 hasRelatedWork W1992668655 @default.
- W2103362546 hasRelatedWork W2036530632 @default.
- W2103362546 hasRelatedWork W2037560904 @default.
- W2103362546 hasRelatedWork W2068519900 @default.
- W2103362546 hasRelatedWork W2133176115 @default.
- W2103362546 hasRelatedWork W2187830633 @default.
- W2103362546 hasRelatedWork W2331527897 @default.
- W2103362546 hasVolume "2" @default.
- W2103362546 isParatext "false" @default.
- W2103362546 isRetracted "false" @default.
- W2103362546 magId "2103362546" @default.
- W2103362546 workType "article" @default.